The data are incrementally positive but from open-label extensions, not randomized controlled trials. The key catalysts are the Phase 3 ALKIVIA topline in Q3 2026 and UNITY in H2 2027. Traders should monitor for potential stock moves around those readouts. Near-term, the EULAR data alone are unlikely to drive sustained re-rating without confirmatory Phase 3 results.
ARGX drugs
ARGX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $813.14entry
- T+1 · 6mo ago +3.58%α +3.18% · $842.27
- T+5 · 5mo ago +6.03%α +9.85% · $862.18
- T+20 · 5mo ago +15.56%α +16.56% · $939.68
- T+60 · 3mo ago +30.22%α +27.72% · $1,058.90
Price Chart
How similar events traded
Executive Summary
Argenx presented new long-term data for efgartigimod in myositis (ALKIVIA+ open-label extension) and Sjogren's disease (RHO+ extension) at EULAR 2026, showing sustained clinical benefit and consistent safety. Topline Phase 3 results for myositis (ALKIVIA) are expected in Q3 2026, and for Sjogren's (UNITY) in H2 2027. The data reinforce the FcRn mechanism in rheumatology but are interim open-label results, not pivotal.
Key Facts
- ALKIVIA+ myositis data at 52 weeks: 37.5% of continuous efgartigimod patients maintained major TIS improvement; mean TIS 52.19 for continuous arm, 49.62 for placebo-switch arm.
- RHO+ Sjogren's data at 72 weeks: median ClinESSDAI scores low at 2.5 (efgartigimod arm) and 2.0 (placebo-switch arm); maintenance of response on biweekly dosing.
- Cross-indication safety analysis: consistent profile across 834 treated patients and >1,300 patient-years of follow-up.
- Topline Phase 3 ALKIVIA (myositis) results expected Q3 2026; Phase 3 UNITY (Sjogren's) topline expected H2 2027.
- Phase 2 eSScape study design for systemic sclerosis presented; no data yet.
Financial Impact
No financial figures reported. Positive clinical data supports pipeline value for efgartigimod in two new indications (myositis, Sjogren's) with combined addressable market potentially in the billions, but no revenue or cost estimates provided.
Risk Factors
- Phase 3 ALKIVIA (myositis) may fail to meet primary endpoint despite Phase 2 signal.
- Phase 3 UNITY (Sjogren's) topline not expected until H2 2027; long wait with binary risk.
- Open-label extension data are subject to selection bias and lack placebo control.
- Competition from other FcRn blockers and alternative therapies in rheumatology.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-069786 |
| Document: tm2616678d1_6k.htm | 0001104659-26-069786 |
| Document: 0001104659-26-069786-index-headers.html | 0001104659-26-069786 |
| Document: 0001104659-26-069786-index.html | 0001104659-26-069786 |
| Document: 0001104659-26-069786.txt | 0001104659-26-069786 |
Track record
23 reports on ARGX
6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.35% at T+20 after the Aug 6, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
- Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
- Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers